{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:10:50Z","timestamp":1784977850431,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004791","name":"Peking University","doi-asserted-by":"publisher","award":["2018SF038 (C.Y.C.)"],"award-info":[{"award-number":["2018SF038 (C.Y.C.)"]}],"id":[{"id":"10.13039\/501100004791","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.clinthera.2020.05.019","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T17:34:28Z","timestamp":1595612068000},"page":"1494-1507.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials"],"prefix":"10.1016","volume":"42","author":[{"given":"Chaoyang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-1005","authenticated-orcid":false,"given":"Yimin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2020.05.019_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2013.0215","article-title":"NCCN Task Force report: bone health in cancer care","volume":"11","author":"Gralow","year":"2013","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"suppl 3","key":"10.1016\/j.clinthera.2020.05.019_bib2","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"ESMO Guidelines Working Group. Bone health in cancer patients: ESMO clinical practice guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"issue":"8 Suppl","key":"10.1016\/j.clinthera.2020.05.019_bib3","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2020.05.019_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2020.05.019_bib5","first-page":"717","article-title":"Clinical features and prognostic factors in patients with esophageal cancer with bone metastasis","volume":"19","author":"Imura","year":"2020","journal-title":"Oncol Lett"},{"issue":"3 Suppl","key":"10.1016\/j.clinthera.2020.05.019_bib6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/COC.0b013e3181deb9e5","article-title":"Bone continuum of cancer","volume":"33","author":"Lipton","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clinthera.2020.05.019_bib7","first-page":"879","article-title":"Impact of skeletal complications on patients' quality of life, mobility, and functional independence [published correction appears in Support Care Cancer. 2008;16:1201]","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2020.05.019_bib8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","article-title":"Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007)","volume":"129","author":"Yong","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"20 Pt 2","key":"10.1016\/j.clinthera.2020.05.019_bib9","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2020.05.019_bib10","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2020.05.019_bib11","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO.2017.76.6402","article-title":"Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update","volume":"36","author":"Anderson","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2020.05.019_bib12","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update","volume":"35","author":"Van Poznak","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2020.05.019_bib13","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.19.03148","article-title":"Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a Cancer Care Ontario guideline [Epub ahead of print 2020 Jan 28]","volume":"38","author":"Saylor","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2020.05.019_bib14","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A\u00a0randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2020.05.019_bib15","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2020.05.019_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ctrv.2005.09.004","article-title":"Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence","volume":"31","author":"Smith","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clinthera.2020.05.019_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025600","article-title":"Database analysis of the risk factors of bisphosphonate-related osteonecrosis of the jaw in Hungarian patients","volume":"9","author":"Veszelyn\u00e9 Kot\u00e1n","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2020.05.019_bib18","series-title":"Zometa (Zoledronic Acid) Injection, for Intravenous Use [prescribing Information]","year":"2018"},{"key":"10.1016\/j.clinthera.2020.05.019_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.clinthera.2020.05.019_bib20","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A\u00a0single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.clinthera.2020.05.019_bib21","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.05.019_bib22","series-title":"Xgeva (Denosumab) Injection, for Intravenous Use [prescribing Information]","year":"2018"},{"key":"10.1016\/j.clinthera.2020.05.019_bib23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2020.05.019_bib24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9768","key":"10.1016\/j.clinthera.2020.05.019_bib25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2020.05.019_bib26","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2020.05.019_bib27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/CMAR.S174731","article-title":"The history of cancer pain and bone-targeted agents: 10 most commonly asked questions","volume":"11","author":"Vieira","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clinthera.2020.05.019_bib28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1634\/theoncologist.2014-0328","article-title":"Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis","volume":"20","author":"Wang","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2020.05.019_bib29","article-title":"Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours","volume":"26","author":"Zheng","year":"2017","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.clinthera.2020.05.019_bib30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1159\/000447372","article-title":"Safety of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials","volume":"39","author":"Chen","year":"2016","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.clinthera.2020.05.019_bib31","first-page":"1029","article-title":"Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Menshawy","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2020.05.019_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"Plos Med"},{"key":"10.1016\/j.clinthera.2020.05.019_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"Plos Med"},{"key":"10.1016\/j.clinthera.2020.05.019_bib34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.critrevonc.2019.04.020","article-title":"The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone","volume":"139","author":"Hussain","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clinthera.2020.05.019_bib35","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cncr.21104","article-title":"Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect","volume":"104","author":"Corso","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2020.05.019_bib36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clinthera.2020.05.019_bib37","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1038\/bcj.2015.96","article-title":"Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial","volume":"6","author":"Raje","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clinthera.2020.05.019_bib38","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2020.05.019_bib39","first-page":"679","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2020.05.019_bib40","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1248\/bpb.b15-00385","article-title":"Incidence and risk factors of osteonecrosis of the jaw in advanced cancer patients after treatment with zoledronic acid or denosumab: a retrospective cohort study","volume":"38","author":"Kajizono","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.clinthera.2020.05.019_bib41","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jcms.2013.05.038","article-title":"Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection","volume":"41","author":"Otto","year":"2013","journal-title":"J\u00a0Craniomaxillofac Surg"},{"key":"10.1016\/j.clinthera.2020.05.019_bib42","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/jop.12646","article-title":"Denosumab-related osteonecrosis of the jaw: a retrospective study","volume":"47","author":"Egloff-Juras","year":"2018","journal-title":"J\u00a0Oral Pathol Med"},{"key":"10.1016\/j.clinthera.2020.05.019_bib43","first-page":"e326","article-title":"Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab vs zoledronic acid: a systematic review and meta-analysis","volume":"25","author":"Limones","year":"2020","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.clinthera.2020.05.019_bib44","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/os.12338","article-title":"Multicenter study on observation of acute-phase responses after infusion of zoledronic acid 5\u2009mg in Chinese women with postmenopausal osteoporosis","volume":"9","author":"Ding","year":"2017","journal-title":"Orthop Surg"},{"key":"10.1016\/j.clinthera.2020.05.019_bib45","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/jcpt.13004","article-title":"Evaluating the impact of regulatory action on denosumab-induced hypocalcaemia in Japan","volume":"44","author":"Imatoh","year":"2019","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2020.05.019_bib46","first-page":"321","article-title":"Bone metastases: an overview","volume":"11","author":"Macedo","year":"2017","journal-title":"Oncol Rev"},{"key":"10.1016\/j.clinthera.2020.05.019_bib47","first-page":"21","article-title":"The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials","volume":"9","author":"Zhang","year":"2017","journal-title":"J\u00a0Bone Oncol"},{"key":"10.1016\/j.clinthera.2020.05.019_bib48","first-page":"100212","article-title":"A\u00a0real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe","volume":"14","author":"Body","year":"2018","journal-title":"J\u00a0Bone Oncol"},{"key":"10.1016\/j.clinthera.2020.05.019_bib49","first-page":"37","article-title":"Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States","volume":"23","author":"Stopeck","year":"2020","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.clinthera.2020.05.019_bib50","article-title":"Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany","author":"Diel","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2020.05.019_bib51","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.19.03148","article-title":"Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline","volume":"38(15)","author":"Saylor","year":"2020","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clinthera.2020.05.019_bib52","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","article-title":"Hypocalcaemia in patients with metastatic bone disease treated with denosumab","volume":"51","author":"Body","year":"2015","journal-title":"Eur J Cancer"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820302812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820302812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:52:49Z","timestamp":1758963169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820302812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0149291820302812"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.05.019","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}